목차
Key Takeaways 1
Introduction 3
Why the 9- vs. 13-Year Distinction? 4
The Economics of Biopharmaceutical Innovation 5
Small Molecules 7
How They Work 7
Diseases They Treat 7
Production Cost 10
Large Molecules (Biologics) 10
How They Work 10
Diseases They Treat 10
Production Cost 11
Implications of the IRA’s 9- vs. 13-Year Distinction 11
Reduced R&D Leading to Fewer Treatment Options 11
Decreased Funding for Small Pharmaceutical Companies 14
The EPIC Act 15
Conclusion 15
Endnotes 17
